Journal article
Urine hepcidin has additive value in ruling out cardiopulmonary bypass-associated acute kidney injury: an observational cohort study
Anja Haase-Fielitz, Peter R Mertens, Michael Plass, Hermann Kuppe, Roland Hetzer, Mark Westerman, Vaughn Ostland, John R Prowle, Rinaldo Bellomo, Michael Haase
CRITICAL CARE | BMC | Published : 2011
DOI: 10.1186/cc10339
Abstract
INTRODUCTION: Conventional markers of acute kidney injury (AKI) lack diagnostic accuracy and are expressed only late after cardiac surgery with cardiopulmonary bypass (CPB). Recently, interest has focused on hepcidin, a regulator of iron homeostasis, as a unique renal biomarker. METHODS: We studied 100 adult patients in the control arm of a randomized, controlled trial http://www.clinicaltrials.gov/NCT00672334 who were identified as being at increased risk of AKI after cardiac surgery with CPB. AKI was defined according to the Risk, Injury, Failure, Loss, End-stage renal disease classification of AKI classification stage. Samples of plasma and urine were obtained simultaneously (1) before CP..
View full abstractGrants
Funding Acknowledgements
We thank Argid Rutenberg and Raimund Rutenberg for their excellent research assistance. This study was supported by grants from the German Heart Foundation (Deutsche Stiftung fur Herzforschung) and from the Else Kroner-Fresenius-Stiftung, Germany.MW is a shareholder, president and chief executive officer of Intrinsic LifeSciences, a developer and distributor of an enzyme-linked immunosorbent assay for hepcidin. MW has received consulting fees and grant support from Centocor-Ortho Research and Development. JRP and RB are named in a US preliminary patent application in conjunction with MW. RB has received consulting fees from Gambro, Biosite, Abbott Diagnostics and Philips Medical Systems, as well as grant support from Fresenius Kabi, Bard, Pfizer and Gambro. MH received lecture fees from Abbott Diagnostics and Biosite/Alere.